Lenalidomide Eugia

Lenalidomide, the active ingredient in Lenalidomide Eugia, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is employed in the management of multiple myeloma and myelodysplastic syndromes, targeting malignant plasma cells and abnormal hematopoietic clones in adult patients.

GNH USA supplies Lenalidomide Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing under stringent quality standards and adhering to European Union regulatory requirements throughout the supply chain.

Lenalidomide is indicated for hematologic malignancies and related bone‑marrow disorders, where it modulates immune response and inhibits tumor growth.

- Multiple Myeloma: Reduces disease progression and improves survival in adult patients. - Myelodysplastic Syndromes with del(5q): Improves blood counts and reduces transfusion dependence. - Relapsed or Refractory Multiple Myeloma: Provides therapeutic benefit after prior treatments have failed.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue - Neutropenia - Diarrhea - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia with infection risk - Secondary primary malignancies

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risk.

- Monitor blood counts: Perform regular complete blood count assessments. - Assess thromboembolic risk: Consider prophylactic anticoagulation in high‑risk patients. - Contraindicated in pregnancy: Avoid use in pregnant women and ensure effective contraception. - Adjust for renal impairment: Dose may need modification in patients with reduced kidney function. - Review concomitant drugs: Evaluate for potential interactions before initiating therapy. - Store at below 25°C: Keep in the original packaging, protect from moisture and light.

Lenalidomide interacts with several medicines; awareness of these interactions helps optimize therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): Heightened risk of bleeding. - Thalidomide or pomalidomide: Additive teratogenic and hematologic toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): May reduce efficacy. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): Potential for increased bleeding. - Live vaccines: May diminish vaccine effectiveness.